177 related articles for article (PubMed ID: 37332119)
1. A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation.
Mega A; Mebrahtu A; Aniander G; Ryer E; Sköld A; Sandegren A; Backström Rydin E; Rockberg J; Östman A; Frejd FY
MAbs; 2023; 15(1):2223750. PubMed ID: 37332119
[TBL] [Abstract][Full Text] [Related]
2. Co-culture platform for tuning of cancer receptor density allows for evaluation of bispecific immune cell engagers.
Mebrahtu A; Aniander G; Mega A; Moradi Barzadd M; Berndt Thalén N; Gudmundsdotter L; Backström Rydin E; Sandegren A; Frejd FY; Rockberg J
N Biotechnol; 2024 Mar; 79():120-126. PubMed ID: 38159596
[TBL] [Abstract][Full Text] [Related]
3. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
4. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
6. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
7. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
8. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.
Salomon R; Dahan R
Front Immunol; 2022; 13():940674. PubMed ID: 35911742
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.
Salomon R; Rotem H; Katzenelenbogen Y; Weiner A; Cohen Saban N; Feferman T; Amit I; Dahan R
Nat Cancer; 2022 Mar; 3(3):287-302. PubMed ID: 35190724
[TBL] [Abstract][Full Text] [Related]
10. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Sum E; Rapp M; Fröbel P; Le Clech M; Dürr H; Giusti AM; Perro M; Speziale D; Kunz L; Menietti E; Brünker P; Hopfer U; Lechmann M; Sobieniecki A; Appelt B; Adelfio R; Nicolini V; Freimoser-Grundschober A; Jordaan W; Labiano S; Weber F; Emrich T; Christen F; Essig B; Romero P; Trumpfheller C; Umaña P
Clin Cancer Res; 2021 Jul; 27(14):4036-4053. PubMed ID: 33771854
[TBL] [Abstract][Full Text] [Related]
12. The influence of CD40 ligation and interferon-gamma on functional properties of human monocyte-derived dendritic cells activated with polyinosinic-polycytidylic acid.
Dragicević A; Dzopalić T; Vasilijić S; Vucević D; Bozić B; Majstorović I; Balint B; Colić M
Vojnosanit Pregl; 2011 Apr; 68(4):301-8. PubMed ID: 21627015
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
[TBL] [Abstract][Full Text] [Related]
14. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
16. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy.
Enell Smith K; Deronic A; Hägerbrand K; Norlén P; Ellmark P
Expert Opin Biol Ther; 2021 Dec; 21(12):1635-1646. PubMed ID: 34043482
[No Abstract] [Full Text] [Related]
17. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
18. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
19. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2306782120. PubMed ID: 37607227
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
Knorr DA; Dahan R; Ravetch JV
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11048-11053. PubMed ID: 30297432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
